Critical Comparison: Iqvia (IQV) vs. The Competition

Iqvia (NYSE: IQV) is one of 185 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its peers? We will compare Iqvia to related businesses based on the strength of its institutional ownership, analyst recommendations, risk, profitability, dividends, valuation and earnings.

Analyst Ratings

This is a breakdown of current ratings for Iqvia and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Iqvia 0 8 8 0 2.50
Iqvia Competitors 543 2453 6662 127 2.65

Iqvia presently has a consensus price target of $106.06, suggesting a potential upside of 6.72%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 13.64%. Given Iqvia’s peers stronger consensus rating and higher possible upside, analysts clearly believe Iqvia has less favorable growth aspects than its peers.

Institutional & Insider Ownership

95.8% of Iqvia shares are held by institutional investors. Comparatively, 49.9% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 6.4% of Iqvia shares are held by company insiders. Comparatively, 14.5% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Risk & Volatility

Iqvia has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500. Comparatively, Iqvia’s peers have a beta of 1.57, indicating that their average share price is 57% more volatile than the S&P 500.

Profitability

This table compares Iqvia and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Iqvia 0.58% 12.60% 4.65%
Iqvia Competitors -4,596.32% -479.06% -43.44%

Earnings and Valuation

This table compares Iqvia and its peers gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Iqvia $6.88 billion $115.00 million 342.70
Iqvia Competitors $217.36 million -$39.57 million -64.98

Iqvia has higher revenue and earnings than its peers. Iqvia is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Summary

Iqvia beats its peers on 7 of the 13 factors compared.

Iqvia Company Profile

IQVIA Holdings Inc., formerly Quintiles IMS Holdings, Inc., provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services. The Research & Development Solutions segment provides biopharmaceutical development services. It offers project management and clinical monitoring, clinical trial support services, Q2 solutions, and strategic planning and design. The Integrated Engagement Services segment offerings include healthcare provider engagement services, patient engagement services, and scientific strategy and medical affairs services. The Company has its operations in the Americas, Europe and Africa, and the Asia-Pacific.

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit